Table 6.
List of examples of drugs developed using solid lipid nanoparticle technology.
| Drug | Lipid used | Biopharmaceutical application |
|---|---|---|
| 5-Fluoro uracil | Dynasan 114 and Dynasan 118 | Prolonged release in simulated colonic media |
| Apomorphine | Glycerylmonostearate, polyethylene glycol monostearate | Enhanced bioavailability in rats |
| Calcitonin | Trimyristin | Improvement of the efficacy of proteins |
| Clozapine | Trimyristin, Tristearin and Tripalmitin | Improvement of bioavailability |
| Cyclosporin A | Glycerylmonostearate and glycerylpalmitostearate. | Controlled release |
| Gonadotropin release hormone | Monostearin | Prolonged release |
| Ibuprofen | Stearic acid, Triluarin and Tripalmitin | Stable formulation with low toxicity |
| Idarubicin | Emulsifying wax | Delivery of oral proteins |
| Insulin | Stearin acid, octadecyl alcohol, cetylpalmitate, glycerylpalmitostearate, glyceryltripalmitate, glycerylbehenate and glycerylmonostearate. | Potential for oral delivery of proteins. |
| Lopinavir | Campritol 888 ATO | Bioavailability enhanced |
| Nimusulide | Glycerylbehanate, palmitostearate, glyceryltristearate | Sustained release of drug |
| Progesterone | Monostearin, stearic acid and oleic acid | Potential for oral drug delivery |
| Repaglinide | Glycerylmonostearate and tristearin | Reduced toxicity |
| Tetracycline | Gycerylmonostearate and stearic acid | Sustained release |